- Open Access
Reducing malaria burden and accelerating elimination with long-lasting systemic insecticides: a modelling study of three potential use cases
Malaria Journalvolume 18, Article number: 307 (2019)
While bed nets and insecticide spraying have had significant impact on malaria burden in many endemic regions, outdoor vector feeding and insecticide resistance may ultimately limit their contribution to elimination and control campaigns. Complementary vector control methods such as endectocides or systemic insecticides, where humans or animals are treated with drugs that kill mosquitoes upon ingestion via blood meal, are therefore generating much interest. This work explores the conditions under which long-lasting systemic insecticides would have a substantial impact on transmission and burden.
Hypothetical long-lasting systemic insecticides with effective durations ranging from 14 to 90 days are simulated using an individual-based mathematical model of malaria transmission. The impact of systemic insecticides when used to complement existing vector control and drug campaigns is evaluated in three settings—a highly seasonal high-transmission setting, a near-elimination setting with seasonal travel to a high-risk area, and a near-elimination setting in southern Africa.
At 60% coverage, a single round of long-lasting systemic insecticide with effective duration of at least 60 days, distributed at the start of the season alongside a seasonal malaria chemoprevention campaign in a high-transmission setting, results in further burden reduction of 30–90% depending on the sub-populations targeted. In a near-elimination setting where transmission is sustained by seasonal travel to a high-risk area, targeting high-risk travellers with systemic insecticide with effective duration of at least 30 days can result in likely elimination even if intervention coverage is as low as 50%. In near-elimination settings with robust vector control, the addition of a 14-day systemic insecticide alongside an anti-malarial in mass drug administration (MDA) campaigns can decrease the necessary MDA coverage from about 85% to the more easily achievable 65%.
While further research into the safety profile of systemic insecticides is necessary before deployment, models predict that long-lasting systemic insecticides can play a critical role in reducing burden or eliminating malaria in a range of contexts with different target populations, existing malaria control methods, and transmission intensities. Continued investment in lengthening the duration of systemic insecticides and improving their safety profile is needed for this intervention to achieve its fullest potential.
Following the renewed global call for eradication, the widespread rollout of insecticide-treated nets (ITNs), and increased usage of artemisinin-based combination therapy for first-line treatment, malaria burden has declined substantially over the last decade . Yet malaria remains recalcitrant in many areas, including high-burden countries where progress has stalled or reversed in the last few years  as well as near-elimination areas where interruption of transmission continues to remain out of reach.
In areas where malaria persists despite high usage of ITNs, outdoor exposure can contribute a major share of residual transmission . Insecticide resistance is increasingly widespread, diminishing the community benefits of ITNs and potentially erasing much of the gains made in the last 20 years of malaria control [4, 5]. Continued innovation along the path to eradication is needed to address both challenges.
One potential avenue for complementing the existing toolset is the use of systemic insecticides, known as endectocides when they also have antiparasitic properties, to reduce vector populations. Ivermectin has been distributed in mass drug administrations (MDA) for onchocerciasis and lymphatic filariasis , and is lethal to mosquitoes upon ingestion during blood feeding on humans or animals [6,7,8,9]. However, ivermectin has a short half-life of under 4 days in large mammals  and 12–36 h in humans . While higher doses have been used to treat scabies, for example, at the currently approved standard doses given for treating non-malarial diseases, ivermectin concentrations in human blood can maintain mosquitocidal effects for approximately 48 h [8, 12], which is predicted to be too short to have much impact on malaria burden . While the low concentrations of ivermectin observed 28 days post-dose continue to have a small impact on mosquito survival , the epidemiological relevance is unknown. The duration of ivermectin efficacy can be extended via multiple doses over the course of weeks, but this could prove operationally challenging to deliver at scale. There has been recent interest in developing longer-lasting systemic insecticide formulations for malaria control and potential elimination, including slow release formulations [8, 12] and high-dose ivermectin, which has been observed to reduce mosquito survival 28 days post-treatment in a study of outpatients at a hospital in Kenya . A recent study in Burkina Faso observed a 20% reduction in clinical incidence in an intervention group receiving ivermectin 6 times over 18 weeks at 3 week intervals, with young children, pregnant women, and women nursing newborns excluded from MDA eligibility . Another drug class, isoxazolines, shows promise to maintain mosquitocidal activity up to 50–90 days based on allometric scaling of preclinical pharmacokinetic data , although safety concerns still need to be addressed .
Previous mathematical modelling has suggested that high-dose ivermectin can improve the impact of anti-malarial MDAs , a new long-lasting systemic insecticide with high efficacy lasting 30 days can substantially reduce burden when distributed with seasonal malaria chemoprevention (SMC) , slow release formulations delivering a sustained therapeutic dose over 14 days can boost efficacy of mass drug administration with the goal of elimination , and MDA with an isoxazoline lasting 90 days can also reduce burden in high-transmission areas . However, there has not been a systematic exploration of the potential impact of long-lasting systemic insecticides across multiple use cases within the same modelling framework. With the aim of describing the conditions under which safe and long-lasting systemic insecticides would be potentially beneficial and thus informing decision-making by funders of technology development, the ability of generic hypothetical systemic insecticides lasting 14 to 90 days to achieve the following goals is tested: additional burden reduction in the context of SMC, targeted elimination in the context of human travel to high-risk areas, and local elimination in the context of outdoor-biting vectors or insufficient coverage with traditional vector control interventions. Models predict that long-lasting systemic insecticides can complement other interventions to help reduce burden and achieve elimination. Systemic insecticides increase the impact of drug campaigns or alternatively can be used to achieve the same impact at lower, perhaps more feasible, campaign coverage. Unless systemic insecticides are extremely long-lasting, with mosquitocidal activity up to 90 days post dosage, improving their safety profile such that young children and women of childbearing age can safely participate in MDAs is essential.
All simulations are performed with EMOD v2.15 , an agent-based model of Plasmodium falciparum malaria transmission that includes vector life cycle dynamics , within-host parasite and immune dynamics calibrated to age- and season-stratified asexual and sexual stage parasite densities , and drug pharmacokinetics and pharmacodynamics .
Pharmacokinetics of systemic insecticides are modelled as constant efficacy of duration over 14, 30, 60, or 90 days, subsequently referred to as SI-14, SI-30, SI-60, and SI-90 respectively. Vectors feeding on a human with active systemic insecticide have 95% probability of death prior to the next feed, with 3 days between feeds. This corresponds to a hazard ratio of 4.4, which is in line with ivermectin . Systemic insecticides are assumed to have identical impact on all vector species and no impact of the systemic insecticide on parasite load. All models include surface area dependent biting, where children are less likely to be bitten by vectors due to their smaller size. This framework is able to capture effect sizes similar to those observed in the field with ivermectin that lasts around 3 days (Additional file 1) .
No resistance to anti-malarials or to systemic insecticide is assumed. In each of the scenarios, coverage refers to the target demographic and not the entire population. For example, 50% coverage in a cohort excluding women of childbearing age and children under 5 would refer to 50% of males over 5 and females between the ages of 5 and 12 and over 51 years of age receiving the systemic insecticide.
Burden reduction scenarios
A simulation model of a well-mixed village is constructed based on northern Nigeria, with Sahelian seasonality and high-intensity transmission of annual entomological inoculation rate (EIR) 110 and mean annual all-age true prevalence of any infection of around 90% in the absence of any interventions. The vector population is modelled as Anopheles gambiae mosquitoes with 65% anthropophily and 90% indoor biting. Total human population is around 1000 individuals with birth and death rates of 45 per 1000 per year.
Drug campaigns are timed to start on June 28, just prior to the wet season, and the number of clinical cases averted is calculated for the year after the start of the campaign. Clinical cases are defined as malarial fevers of at least 38.5 °C occurring at least 14 days since the previous fever. SMC campaigns are carried out with dihydroartemisinin–piperaquine (DP), which has a 30-day period of prophylactic protection. SMC is distributed as 4 rounds separated by 1 month, with independent coverage between rounds, and targeted at children under 5 in standard SMC or children under 10 in expanded SMC. Systemic insecticide MDAs are given once, concurrently with the first round of SMC. Three systemic insecticide distribution scenarios are tested: where children under 5 and women of childbearing age (12–51 years)  are ineligible to receive long-lasting systemic insecticides; where children under 5 are ineligible to receive long-lasting systemic insecticides but women of childbearing age are eligible; and where everyone is eligible to receive long-lasting systemic insecticides.
In all scenarios, the relative reduction in total clinical burden (number of clinical malaria cases in all age groups) is measured and compared with a standard SMC campaign in children under 5. Coverage of SMC and systemic insecticide MDA are assumed to be equivalent, although the denominators differ. Fifty stochastic realizations are run for each drug campaign and coverage combination. No other interventions are included in the simulations.
Targeted elimination scenarios
A simulation model of a transmission ecosystem of two villages that share a high-risk area is constructed (Fig. 3a) . Transmission is seasonal, peaking in December, and annual mean all-age prevalence of any infection is 29% in the absence of interventions. All villagers can travel between the villages, but only high-risk travellers visit the high-risk area. Each village is home to about 280 people and there is no importation from outside the modelled areas. Village vectors are Anopheles minimus and vectors in the high-risk area are Anopheles dirus, with 40% and 99% outdoor biting, respectively . Both vector species are modelled with 50% anthropophily and the systemic insecticides are assumed to have the same effect on both species.
High-risk travellers are 70% of people between ages 15 and 35. Migration happens between April and August with a mean stay duration of 30 days. During each month of high-risk travel, 50% of high-risk travellers who are currently at home in their village can make a trip to the high-risk area. Equal gender representation in the high-risk traveller population is assumed.
Treatment with artemether–lumefantrine (AL) is available in both villages for symptomatic cases. 80% of clinical malaria cases in children under 10 receive treatment, 70% of clinical cases in individuals over 10 receive treatment, and 95% of severe cases receive treatment. When treatment is sought, it is received within 3 days of symptom onset. High-risk travellers seek care at a lower (40%) and slower (within 5 days) rate. No treatment is available in the high-risk area and no other vector control is simulated.
All simulations last 3 years. The following drug combinations are considered: distribution of DP only, systemic insecticide only, and DP in combination with systemic insecticide. Children under 5 and women of childbearing age (12–51 years) are ineligible to receive systemic insecticides unless otherwise indicated but can still receive DP. MDA distributions occur only in year 1 and include three independent rounds separated by 30 days, beginning in June. MDA is never distributed in the high-risk area, and coverage refers to the fraction of eligible individuals residing in the village on the date of distribution who receive drugs. In scenarios where individuals receive drugs when they depart the village for the high-risk area, these trip-based drug distributions occur during all years. Coverage refers to the probability that drugs are taken for any given trip to the high-risk area by an eligible individual, and there are no restrictions on the number of times a person can take drugs.
Elimination is defined as zero infected individuals in the entire modelled area, including the high-risk area, and is assessed at the end of the third year. Each scenario is run for 100 stochastic realizations.
Southern Africa elimination scenarios
A simulation model of a 10,000-person population centre is constructed as 332 separate 1 km2 grid cells. About half of the population is located in a dense central area comprised of about a dozen grid cells, while the rest of the population is distributed more sparsely in the outlying areas. Individuals have a daily probability to take overnight trips to other grid cells, according to a gravity model of migration. The gravity model is parametrized to human movement on scales of one to tens of kilometres observed in geotagged campaign data from a rural site in Zambia (unpublished data). A distance exponent of 1.1 and a population exponent of 0.95 are used, with an overall amplitude such that individuals take an average of 5 overnight trips per year; the results are not sensitive to these choices. There is no disease importation from outside the modelled area.
Transmission intensity and seasonality reflect southern Africa, with two vector species: Anopheles arabiensis (80% of vectors) and Anopheles funestus (20% of vectors) [27, 28]. Both vector species are assumed to have 65% anthropophily, with 50% indoor biting for An. arabiensis and 90% for An. funestus. All-age parasite prevalence by rapid diagnostic test (RDT) fluctuates between 20% and 40% prior to any vector control or MDA. All simulations begin with identical pre-intervention transmission intensity. When presenting with a clinical episode, 60% of children under 5 and 40% of individuals over 5 receive treatment. 80% of severe clinical episodes are treated for all age groups. Cases that receive care are treated with AL.
Intervention scenarios are simulated for 4 years (Fig. 4a). ITN distributions occur on September 1st of years 1 and 3. ITN killing efficacy starts at 60% and exponentially decays with a time constant of 4 years, which corresponds to a half-life of roughly 2.7 years. ITN blocking efficacy starts at 90% and exponentially decays with a time constant of 2 years, which corresponds to a half-life of roughly 1.4 years. Individuals aged 5 to 20 years old are 10% less likely to use a net . Modelled ITN usage is seasonal, with a maximum of 100% of ITN owners using their net on January 1st, reaching its minimum of 50% in June. To capture incomplete net retention, 60% of the population is modeled as discarding their nets at a rate with exponential time constant 260 days and the remaining 40% of individuals modeled as keeping their nets for much longer, discarding with an exponential decay time constant of 2160 days [30, 31]. Coverage across ITN distributions is uncorrelated.
IRS spraying campaigns occur on September 1st of years 2 and 3. IRS is modeled as an organophosphate insecticide with 90% initial killing rate that lasts for 7 months then rapidly decays  (and unpublished observations from Mara Maquina). Coverage across IRS campaigns is uncorrelated.
MDA campaigns are implemented in both February and November of years 2 and 3, a total of 4 distributions. A small scatter in grid cell-level campaign dates such that each full MDA distribution completes over the course of a few weeks is incorporated. The following drug combinations are tested: DP-only MDA, systemic insecticide-only MDA, and MDA with both DP and systemic insecticide. Coverage across multiple MDA rounds is uncorrelated.
No interventions other than ongoing case management are implemented in year 4. Elimination is defined as zero infected individuals in the entire simulated area at the end of year 4. Each intervention scenario is simulated with 100 stochastic realizations.
Systemic insecticides lasting at least 60 days reduce burden when given in combination with SMC
The Sahelian setting is characterized by a single peak transmission season and low levels of biting throughout the remainder of the year (Fig. 1a). In a recent study, systemic insecticides were distributed over 6 rounds at 3-week intervals, to everyone excluding young children, pregnant women, and women nursing infants under 1 week old, resulting in a 20% drop in clinical incidence . However, short-duration systemic insecticides distributed over multiple rounds may prove operationally challenging at scale, especially during the wet season. Considering this, the existing operational framework of SMC, where children under 5 are given monthly malaria chemoprevention, can be leveraged to distribute a single round of long-lasting systemic insecticide with the first round of SMC just as the wet season begins, making it a more tractable intervention configuration for further gains in burden reduction.
Figure 1b shows the proportion of cases remaining after SMC that are averted with systemic insecticide MDA when all individuals can receive systemic insecticides. As coverage increases, the absolute number of cases available for the systemic insecticide MDA to avert decreases since the SMC campaign is having a greater impact. The model predicts that only SI-60 and SI-90 have meaningful impact on reducing clinical burden. A single round of MDA with systemic insecticides of duration 30 days or less is unlikely to boost the impact of a standard SMC campaign in children under 5. At 60% coverage, SI-90 results in 80% further reduction in burden while SI-30 results in under 10% further reduction in burden compared to a standard SMC campaign at 60% coverage.
If only children are excluded from the MDA target population, coverage as low as 40% with SI-90 is sufficient to begin seeing reduction of the remaining burden by over 20% (Fig. 1c). At 60% coverage, simulations predict that SI-60 will also result in around 20% burden reduction, but shorter-lasting systemic insecticides continue to have minimal impact. In children under 5, a 17% reduction in incidence with SI-60 is observed despite this group being excluded from the systemic insecticide MDA (Additional file 2 row B), which is similar to results from the field trial of 6 MDA rounds of ivermectin .
The scenario where both children under 5 and women of childbearing age (12–51 years) are ineligible to receive long-lasting systemic insecticides is considered in (Fig. 1d), which describes a case where systemic insecticide safety in young children and pregnant women has not yet been established and pregnancy testing is unavailable during MDA. These populations do not enter into the denominator of coverage calculations for the MDA. Under this restricted distribution scenario, only SI-90 resulted in substantial additional reduction in clinical burden relative to SMC alone, and furthermore MDA coverage of at least 60% was required. Given that the MDA-eligible population in this scenario consists primarily of adult men, achieving high coverage may be particularly operationally challenging .
At 60% coverage, adding systemic insecticides to a standard SMC campaign results in a 20% drop in annual EIR with SI-14, and a 40% drop in annual EIR with SI-30 even when women of childbearing age and children under 5 are excluded from the systemic insecticide MDA (Additional file 2). When everyone is eligible to receive systemic insecticides at 60% coverage, annual EIR is reduced by 40% and 60% when using SI-14 and SI-30, respectively. However, despite these large drops in EIR, transmission remains high, and only systemic insecticides of durations 60 days or longer reduce EIR to levels that reflect meaningful impact in terms of reduced clinical burden.
A single round of SI-30 or SI-14, concurrently distributed with a standard SMC campaign, has minimal effect on further reducing burden even at 100% coverage. Given safety concerns surrounding the administration of this class of drugs to women of childbearing age  and children under 5 , only long-lasting systemic insecticides of duration 90 days improve burden reduction in a meaningful way. However, in the event this class of drugs is found to be safe for use in nursing and pregnant women, and children under 5 years, a single round of SI-60 in parallel with standard SMC can still further reduce burden with coverage of around 60%.
Compared to a standard SMC campaign, expanding SMC to include children up to the age of 10 reduces burden in all campaigns with or without systemic insecticides (Fig. 1e–g). Without systemic insecticides, the expanded SMC campaign at 40% coverage reduces burden by 20% over a standard SMC campaign. As in the standard SMC use case, systemic insecticides of duration under 30 days do not offer any substantial gains in burden reduction when administered alongside an expanded SMC campaign.
When children under 5 are excluded from the MDA campaign (Fig. 1f), 60% coverage results in 90% reduction in burden with SI-90 while SI-60 requires 100% coverage to offer the same 90% reduction in burden. Excluding children under 5 produces similar results to a campaign where everyone is included (Fig. 1e, f). Just 50% coverage with SI-90 results in over 80% reduction in burden.
When women of childbearing age and children under 5 are excluded from systemic insecticide distribution, 60% coverage with SI-90 results in 80% reduction in burden, and 100% coverage with SI-60 results in just over 80% reduction in burden (Fig. 1g). SI-90 with an expanded SMC campaign, excluding women of childbearing age and children under 5, achieves similar burden reduction as SI-90 with a standard SMC campaign and no restrictions on systemic insecticide eligibility. However, with SI-60 the scenario with expanded SMC eligibility and restricted systemic insecticide eligibility performs better than the scenario with standard SMC and unrestricted systemic insecticide.
The performance of systemic insecticides when distributed with a later round of SMC and when distributed with all rounds of SMC, under conditions where all individuals can receive the insecticide, is shown in Fig. 2. While SI-90 averts the most clinical burden when given with the first SMC round under the simulated seasonal profile (Fig. 1b), SI-60 is optimally given with the second round, and SI-30 and SI-14 should be given with the last round. When timed with the last round, a 60% coverage MDA with SI-14 or SI-30 averts an additional 8 or 22% of clinical cases, respectively. At durations of 60 days and lower, proper timing of systemic insecticide becomes increasingly crucial to achieve good epidemiological impact. Programmes will need to understand their local transmission seasons, which can vary from year to year. In addition, as the wet season progresses, flooding and road washouts can make moving personnel and supplies challenging, and conducting the systemic insecticide distribution as early as possible in the wet season is likely to be logistically simplest. These factors combine to make SI-90 still the best choice for a single-distribution systemic insecticide.
If programme capacity allows for MDA concurrent with all SMC rounds, even SI-14 can avert substantial clinical burden once coverage is moderately high, (Fig. 2d). Consistent with others’ findings , there are little gains to be made by extending endectocide duration above 30 days if coverage of 60% or better is achieved. However, 4 rounds of MDA per year as a control strategy is operationally demanding and may not be cost-effective for programmes relative to other vector control options.
Given the high rates of burden experienced in children under the age of 15 , expanding an SMC campaign to include children up to the age of 10 could be highly beneficial in many high-transmission settings. If duration of systemic insecticide effectiveness is at least 60 days, long-lasting systemic insecticides further reduce burden when added to an SMC campaign. If malaria control programmes have the capacity to distribute multiple rounds of systemic insecticides to older children and adults alongside an SMC campaign, shorter duration systemic insecticides could still be a worthwhile option . Ultimately, safety and cost-effectiveness of the drugs used in systemic insecticide MDA will determine which campaign—expanded or standard SMC with regular or long-lasting systemic insecticides—is most efficacious in reducing burden for a given setting.
Targeting high-risk travellers with long-lasting systemic insecticides can be part of an effective elimination strategy
To explore the potential role of long-lasting systemic insecticides in reaching elimination in low-transmission settings with mobile populations, a system of two villages is simulated. The villages are connected to each other and to a shared high-risk area, which is visited by a subset of villagers (Fig. 3a). Case management for uncomplicated and severe malaria is available in the villages but not in the high-risk area. Transmission in the entire system is low enough that treatment-seeking alone results in interruption of malaria transmission within 3 years in 25% of the simulations.
Two modes of systemic insecticide delivery are considered: (1) as MDA distributed in the villages and (2) given to high-risk travellers as they depart for the high-risk area. Children under 5 and women of childbearing age are assumed to be ineligible to receive systemic insecticide but can still receive DP. In the MDA scenario, achieving elimination with at least 80% probability is possible at operationally feasible coverage with SI-60 when co-administered with DP, or SI-90 if systemic insecticide is given without an anti-malarial (Fig. 3b). MDA with SI-90 requires 70% coverage to achieve 80% probability of elimination without co-administration of DP, or 50% coverage if the MDA also includes DP. Systemic insecticides of shorter duration or DP-only MDA fail to reach 80% probability of elimination even at 100% coverage.
DP-only MDA is as or more successful at elimination at all coverage levels compared with systemic insecticide MDA when systemic insecticide duration is 30 or fewer days. If DP-only MDA is already planned, addition of SI-14 increases probability of elimination by only a small amount. If MDA with systemic insecticide is already planned, addition of DP to the MDA regimen is highly beneficial for all systemic insecticide durations tested, although smaller gains are seen with SI-90, which is already highly successful. If safety concerns in children and pregnant women are alleviated, the combination of DP with SI-30 leads to elimination with 80% probability when coverage is above 80% (Additional file 3).
Compared with MDA, eliminating malaria with a traveller-targeted drug distribution requires lower coverage (Fig. 3c). When systemic insecticide lasts for at least 60 days, coverage as low as 45% results in highly likely elimination, and even DP or SI-30 can eliminate with coverage below 60%. There is some additional gain in performance if systemic insecticide duration is increased above 60 days, as SI-90 requires only 30% coverage to achieve likely elimination. Only 30% coverage is required for likely elimination if travellers are given both DP and systemic insecticide, even if the systemic insecticides lasts only 14 days. The model assumes men and women are equally likely to be high-risk travellers, and thus only half the high-risk trips are eligible to receive systemic insecticide. If this assumption is relaxed, coverage as low as 30% with SI-30 can result in > 80% probability of elimination in the trip-based distribution scenario (Additional file 3). The traveller-targeted strategy requires fewer doses of drug than MDA to achieve the same level of success (Fig. 3d), even though the traveller-targeted strategy is implemented for 3 years while MDA is implemented for one.
Fixing coverage at 60%, systemic insecticide durations from 7 days to 98 days at 1-week increments were sampled, and likelihood of elimination was compared against the DP alternative (Fig. 3e). To outperform DP, systemic insecticide should last at least 40 days when given as MDA or 50 days if given to high-risk travellers. If systemic insecticide can be given to children and women of childbearing age, the minimum duration for systemic insecticide to outperform DP as an elimination drug is reduced to 30 days for MDA and only 20 days for the trip-based distribution.
If only one of the two villages can be reached by either MDA or the trip-based intervention, elimination is still possible, but higher coverage is required (Fig. 3f). Human movement connects populations and is often discussed as a barrier to achieving malaria elimination. In this context, however, when transmission is sustained by movement to a high-risk area where other types of interventions are not easily applied, humans carrying long-acting drugs in their bodies could provide an effective method for delivering vector control to hard-to-reach areas.
Systemic insecticides decrease the MDA campaign coverage needed to interrupt transmission in an integrated intervention strategy
To explore the role of long-lasting systemic insecticides in an elimination strategy that includes traditional vector control and MDA with anti-malarials, a spatially distributed area with southern-Africa-like transmission dynamics is simulated (Fig. 4a). To isolate the intervention effects, the model assumes no importation of infections into this area. Since An. arabiensis comprises about 80% of the vector density, there is a substantial amount of outdoor biting.
Figure 4 shows the likelihood of elimination under four possible underlying vector control packages: no traditional vector control, ITNs only, IRS only, and ITN + IRS. The ITN and IRS coverage, when implemented, is 60%. Under no traditional vector control, an MDA campaign with systemic insecticide is highly unlikely to achieve elimination, unless the systemic insecticide is very long-lasting and coverage is very high: over 70% coverage for SI-90-only MDA or 90% coverage for MDA with SI-60 + DP (Fig. 4b). If the underlying vector control is ITNs alone, the situation is largely the same (Fig. 4c); however, if the underlying vector control is IRS alone, elimination is much more likely (Fig. 4d). This difference is due to two effects: first, significant pyrethroid resistance limiting the ITN killing efficacy was assumed, while for IRS little resistance to the organophosphate was assumed. The second effect is that half the modelled population discards their ITNs within 18 months, whereas the IRS spray, not subject to behavioral factors, is assumed stable for the full 7 months of its duration. In the context of IRS without ITNs, systemic insecticide duration can compensate for MDA coverage (Fig. 4d). To achieve elimination with 80% probability, a DP-only MDA requires 85% coverage, an MDA with DP and SI-14 requires 65% coverage, and an MDA with DP and SI-90 requires only 35% coverage. If the vector control package includes both ITN and IRS, the qualitative picture is similar to the IRS-only case but elimination becomes more feasible across the board, further reducing the MDA coverages needed (Fig. 4e).
When vector control is poor, a systemic insecticide only adds additional benefit to an already-planned MDA with DP if the systemic insecticide duration is greater than 60 days (Fig. 4b, c). In the case of a DP + systemic insecticide MDA drug package combined with a vector control programme including IRS, however, the stronger vector control foundation enables systemic insecticides of any duration to give substantial added benefit alongside DP. Focusing on SI-14, whose duration of activity is close to that of high-dose ivermectin, models predict that SI-14 adds value to a DP-only MDA only when IRS is implemented and when vector control coverage is good but not excellent, above 40% but under 80% (Fig. 5). Below this level of vector control coverage, elimination is highly unlikely and the SI-14 does not have much impact; above this coverage, DP alone is sufficient to make elimination likely. In this intermediate regime of vector control coverage, where many areas that have implemented IRS are likely to lie, adding SI-14 to DP increases the chance of elimination by 10–40%. The synergy between IRS and MDA with anti-malarials has previously been described , and there may be further opportunity to boost this interaction by incorporating systemic insecticide in the MDA.
The alternative use case where a systemic insecticide MDA is already planned was also investigated, and the conditions where adding DP to the MDA adds value were determined. When systemic insecticide is included in an MDA, the addition of DP typically has the strongest effect for SI-14 and SI-30 but has less marginal benefit for longer-lasting systemic insecticides. Figure 5, which focuses exclusively on the impact of SI-14, shows that at any coverage of traditional vector control coverage, adding DP to a 14-day systemic insecticide always increases the probability of elimination. For SI-90, there is minimal benefit from adding DP, while for SI-60, adding DP to the MDA regimen is substantially beneficial only if MDA coverage is high and traditional vector control is poor.
Unlike the SMC and targeted elimination use cases, the Southern Africa scenarios investigated thus far allowed children under the age of 5 and women of childbearing age to receive systemic insecticide. Restricting these populations’ eligibility for systemic insecticide predictably requires higher campaign coverages to have the same effect, by roughly 5–15%, depending on the systemic insecticide duration (Fig. 4f). For SI-14, a restricted systemic insecticide distribution reduces its effectiveness to the point that the systemic insecticide provides very little benefit above a DP-only campaign. For longer-lasting systemic insecticides, even a restricted systemic insecticide + DP campaign has larger impact than a DP-only campaign.
Robust vector control is a crucial foundation towards achieving elimination in the Southern Africa context. Long-lasting systemic insecticides complement but do not replace traditional vector control, nor do they replace anti-malarials during MDA unless the systemic insecticide duration is 90 days. However, including systemic insecticides in an anti-malarial MDA can substantially lower the coverage required to reach elimination, which could be operationally attractive since absence and exclusion criteria can limit the maximum achievable coverage.
In this work, the efficacy of systemic insecticides as a malaria control tool was explored in three different transmission settings: a Sahelian setting with high annual EIR where the goal is burden reduction, a near-elimination setting with a group of adults who regularly visit high-risk areas, and a southern Africa context focusing on elimination as the desired endpoint through vector control and drug campaigns. These diverse settings were selected to identify opportunities where systemic insecticide could provide high value to a pre-existing drug delivery programme, and to explore some of the very different contexts in which additional malaria control tools might help accelerate burden reduction or elimination.
Across the three modelled settings, the use case for including a systemic insecticide is strongest when the systemic insecticide duration is greater than about 30 days in a near-elimination setting, or greater than 60 days in a high-burden setting. Distributing systemic insecticide that lasts only 14 days had little to no impact in all of the modelled settings, unless it was distributed frequently or at the optimum time. In a near-elimination context with robust vector control, good campaign coverage, and, importantly, a safety profile sufficient to be given to small children and women of childbearing age, a 14-day systemic insecticide can be beneficial.
The models predict that systemic insecticides offer the greatest benefit when layered on top of other interventions rather than administered in isolation. In the southern Africa context, elimination is highly unlikely without a foundation of robust vector control, and systemic insecticides add the most benefit when administered alongside an integrated system of vector control and DP drug campaigns; here, the systemic insecticide can substantially reduce the MDA campaign coverage needed to achieve elimination. Lowering the MDA coverage necessary to achieve elimination is an important operational consideration, partly because mobile, high-risk groups are often difficult to reach. However, if these high-risk groups can be targeted directly, for example by treating adults in Southeast Asian settings who enter the deep forest for work with systemic insecticide and DP before they set out, the interventions have an outsize impact on transmission. When close to elimination, trying to target the sources of imported cases may be more cost-effective than continuing to apply interventions in population centres.
Children under the age of 5 and women of childbearing age comprise about 38% of the population in SE Asia and 44% of the population in Sub-Saharan Africa. A systemic insecticide that cannot be safely given to these large portions of the population is more limited in its potential impact, although the models have identified cases where such a restricted systemic insecticide may still be beneficial. To minimize the complexity and cost of MDA programmes, no pregnancy testing was assumed, although if pregnancy testing is an option, many more people would be able to take the systemic insecticide. If a systemic insecticide is unsafe to give to vulnerable subgroups, then to have the same efficacy, either the campaign coverage or the systemic insecticide duration must be increased. For example, in the high-transmission Sahelian context, an unrestricted systemic insecticide of 60-day duration has a similar impact on clinical burden as a restricted systemic insecticide of 90-day duration. In the targeted elimination scenario, systemic insecticide safety restrictions can more than double the systemic insecticide duration necessary to achieve elimination. Prior to approval for new long-lasting systemic insecticides in children and pregnant women, these groups could instead receive regular dose ivermectin . While the safety of ivermectin use in children under 15 kg and pregnant women is inconclusive, current onchocerciasis and lymphatic filariasis programmes have expanded the use of ivermectin and only exclude the severely ill, children under 15 kg, and visibly pregnant women .
The pharmacokinetic and pharmacodynamic properties of systemic insecticides were simplified by assuming a constant killing efficacy over the course of the insecticide’s duration, allowing us to isolate the impact of insecticide duration on epidemiological outcomes; however, this assumption could slightly underestimate the impact of systemic insecticides. The implications for more complex within-host insecticide dynamics can be interpolated from the results presented here. For example, a 300 μg/kg ivermectin dose can be compared with the modelled hypothetical SI-14 . The model also does not incorporate possible non-fatal vector outcomes of the systemic insecticide such as reduced fecundity, nor did were any parasite killing effects modeled since these outcomes are not well understood and the effects are likely secondary to killing the mosquito .
The scenarios presented in this work do not directly incorporate effects of drug or insecticide resistance, the exception being in assuming a low killing efficacy of ITNs in the Southern Africa scenario due to pyrethroid resistance, which is widespread . In settings where resistance is present, systemic insecticides of a shorter duration than 30 or 60 days could still be an important operational tool. Against the backdrop of growing insecticide resistance, systemic insecticides have added utility since they operate by a novel mechanism not shared by current ITN and IRS insecticide compounds, and there is potential for synergy between the insecticides’ killing mechanisms. Against drug resistance, systemic insecticides layered on top of an anti-malarial could also be beneficial, since even if parasites have some protection against the anti-malarial, the systemic insecticide may be able to kill most of the vectors carrying this resistant strain. If systemic insecticide replaces DP entirely for mass administrations, selection pressure could be partially transferred from the parasite onto the vector, making further development of anti-malarial drug resistance less likely.
Anthropophily, the fraction of bites that are taken on a human host, is a critical vector bionomic parameter that is often poorly understood in the local vector context. For a fixed mosquito population size, lowering anthropophily lowers the number of bites on humans and thus reduces the chance of a mosquito transmitting malaria. However, a lower anthropophily also makes the mosquito population more resilient to the impact of vector control methods such as ITN, IRS, or systemic insecticide where vectors encounter vector control while seeking human hosts. The models predict that longer-lasting systemic insecticides are less sensitive to uncertainty in anthropophily than DP or systemic insecticides of duration 30 days or less, and that probability of elimination decreases as anthropophily increases regardless of the drug deployed (Additional file 3). Distribution of systemic insecticides to livestock was not considered, although this strategy may be fruitful where vectors are fairly zoophilic and humans and livestock live in close proximity .
The WHO’s preferred product characteristics for endectocides recommends at least 20% reduction in clinical incidence for one month following administration, and does not make recommendations for product characteristics for elimination purposes . The simulations predict that even SI-14 is likely to meet this target if coverage is at least 50% (Fig. 2d). If distribution of SI-14 is restricted for safety concerns, then the minimum coverage will be higher; however, systemic insecticides with duration at least 30 days are very likely to meet the WHO target even if vulnerable populations are ineligible for administration. Previous work on developing a target product profile for endectocides recommended maintaining hazard ratio above 4 for 30 days post-dose , analogous to the modeled SI-30. This results from this work agree that SI-30 would be highly beneficial if administered with all SMC rounds, and furthermore would be effective in an elimination context when targeted to high-risk travellers.
While this work finds that long-lasting systemic insecticides can yield large benefits in terms of burden reduction or hitting elimination targets, given a good safety profile, co-administration with anti-malarials, and a foundation of robust traditional vector control, the operational challenges and costs of administering MDA should not be ignored when considering this intervention. Other new tools for control of outdoor-biting vectors are also under development, and the cost-effectiveness of systemic insecticides should be compared with other available options.
When distributed in a single round alongside SMC, only systemic insecticides of duration 60 or more days have a meaningful impact on reducing the overall clinical burden. In a near-elimination setting with high-risk travellers, targeting long-lasting systemic insecticides to seasonal high-risk travellers can be a highly effective elimination strategy, more effective than MDA in the general population. In a southern Africa elimination setting that includes existing IRS, ITN, and MDA campaigns with anti-malarials, adding systemic insecticide to the MDA regimen increases the probability of elimination and lowers the MDA coverage required to achieve elimination. Systemic insecticides lasting 40 days or more are more effective than the anti-malarial DP for elimination. However, systemic insecticides of durations between 14 and 30 days can still be effective tools in lower-transmission settings if young children and pregnant and nursing women can be treated safely.
Availability of data and materials
All software used to generate and analyse the data in this manuscript are publicly available or available upon request as described in Additional file 4.
entomological inoculation rate
systemic insecticide with 14-day duration
systemic insecticide with 30-day duration
systemic insecticide with 60-day duration
systemic insecticide with 90-day duration
indoor residual spray
mass drug administration
seasonal malaria chemoprevention
Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–11.
WHO. World malaria report 2018. Geneva: World Health Organization; 2019.
Moshi IR, Manderson L, Ngowo HS, Mlacha YP, Okumu FO, Mnyone LL. Outdoor malaria transmission risks and social life: a qualitative study in South-Eastern Tanzania. Malar J. 2018;17:397.
Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 2008;5:1617–28.
Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H. The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. Elife. 2016;5:e16090.
Brown KR, Ricci FM, Ottesen EA. Ivermectin: effectiveness in lymphatic filariasis. Parasitology. 2000;121(Suppl):S133–46.
Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103:539–47.
Chaccour C, Lines J, Whitty CJM. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113–6.
Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M. Endectocides for malaria control. Trends Parasitol. 2011;27:423–8.
Chaccour C, Abizanda G, Irigoyen Á, Del Pozo JL. Pilot study of a slow-release ivermectin formulation for malaria control in a pig model. Antimicrob Agents Chemother. 2017;61:e02104–16.
Crump A, Ōmura S. Ivermectin, “wonder drug” from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28.
Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, et al. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2016;8:365ra157.
WHO Malaria Policy Advisory Committee. Ivermectin for malaria transmission control: Report of a technical consultation. Geneva: World Health Organization; 2016.
Smit MR, Ochomo EO, Waterhouse D, Kwambai TK, Abong’o BO, Bousema T, et al. Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin–piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL). Clin Pharmacol Ther. 2019;105:388–401.
Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong’o BO, Chen T, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin–piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18:615–26.
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019;393:1517–26.
Miglianico M, Eldering M, Slater H, Ferguson N, Ambrose P, Lees RS, et al. Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. Proc Natl Acad Sci USA. 2018;115:E6920–6.
US Food and Drug Administration (FDA). CVM Updates-Animal Drug Safety Communication: FDA Alerts Pet Owners and Veterinarians About Potential for Neurologic Adverse Events Associated with Certain Flea and Tick Products. 2018. https://www.fda.gov/animal-veterinary/cvm-updates/animal-drug-safety-communication-fda-alerts-pet-owners-and-veterinarians-about-potential-neurologic. Accessed 15 July 2019.
Burrows J, Slater H, Macintyre F, Rees S, Thomas A, Okumu F, et al. A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria. Malar J. 2018;17:462.
Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker RS, et al. Implementation and applications of EMOD, an individual-based multi-disease modeling platform. Pathog Dis. 2018;76:059.
Eckhoff PA. A malaria transmission-directed model of mosquito life cycle and ecology. Malar J. 2011;10:303.
Selvaraj P, Wenger EA, Gerardin J. Seasonality and heterogeneity of malaria transmission determine success of interventions in high-endemic settings: a modeling study. BMC Infect Dis. 2018;18:413.
Gerardin J, Eckhoff P, Wenger EA. Mass campaigns with antimalarial drugs: a modelling comparison of artemether–lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination. BMC Infect Dis. 2015;15:1–14.
Thomas F, Renaud F, Benefice E, De Meeüs T, Guegan J-F. International variability of ages at menarche and menopause: patterns and main determinants. Hum Biol. 2001;73:271–90.
Gerardin J, Bertozzi-Villa A, Eckhoff PA, Wenger EA. Impact of mass drug administration campaigns depends on interaction with seasonal human movement. Int Health. 2018;10:252–7.
Suwonkerd W, Ritthison W, Ngol CT, Tainchum K, Bangs MJ, Chareonviriyahap T. Anopheles mosquitoes—new insights into malaria vectors. In: Manguin S, editor. Vector Biology and Malaria Transmission in Southeast Asia. New York: InTech Open; 2013. p. 273–325.
Sinka ME, Bangs MJ, Manguin S, Rubio-Palis Y, Chareonviriyaphap T, Coetzee M, et al. A global map of dominant malaria vectors. Parasit Vectors. 2012;5:69.
Sinka ME, Golding N, Massey NC, Wiebe A, Huang Z, Hay SI, et al. Modelling the relative abundance of the primary African vectors of malaria before and after the implementation of indoor, insecticide-based vector control. Malar J. 2016;15:142.
Olapeju B, Choiriyyah I, Lynch M, Acosta A, Blaufuss S, Filemyr E, et al. Age and gender trends in insecticide-treated net use in sub-Saharan Africa: a multi-country analysis. Malar J. 2018;17:423.
Bhatt S, Weiss DJ, Mappin B, Dalrymple U, Cameron E, Bisanzio D, et al. Coverage and system efficiencies of insecticide-treated nets in Africa from 2000 to 2017. Elife. 2015;4:e09672.
Gerardin J, Bever CA, Hamainza B, Miller JM, Eckhoff PA, Wenger EA. Optimal population-level infection detection strategies for malaria control and elimination in a spatial model of malaria transmission. PLoS Comput Biol. 2016;12:e1004707.
Dengela D, Seyoum A, Lucas B, Johns B, George K, Belemvire A, et al. Multi-country assessment of residual bio-efficacy of insecticides used for indoor residual spraying in malaria control on different surface types: results from program monitoring in 17 PMI/USAID-supported IRS countries. Parasit Vectors. 2018;11:71.
Nikolov M, Bever CA, Upfill-Brown A, Hamainza B, Miller JM, Eckhoff PA, et al. Malaria elimination campaigns in the Lake Kariba Region of Zambia: a spatial dynamical model. PLoS Comput Biol. 2016;12:1–25.
Elliott RC, Smith DL, Echodu D. Medical and entomological malarial interventions, a comparison and synergy of two control measures using a Ross/Macdonald model variant and openmalaria simulation. Math Biosci. 2018;300:187–200.
Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg? Arch Dis Child. 2018;103:514–9.
Brown KR. Changes in the use profile of Mectizan: 1987–1997. Ann Trop Med Parasitol. 1998;92:61–4.
Slater HC, Walker PGT, Bousema T, Okell LC, Ghani AC. The potential impact of adding Ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972–80.
Ranson H, N’Guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V. Pyrethroid resistance in African Anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol. 2011;27:91–8.
Poché RM, Burruss D, Polyakova L, Poché DM, Garlapati RB. Treatment of livestock with systemic insecticides for control of Anopheles arabiensis in western Kenya. Malar J. 2015;14:351.
WHO. Preferred product characteristics: endectocide for malaria transmission control. Geneva: World Health Organization; 2017.
The authors thank Svetlana Titova for software support and Carlos Chaccour, Janice Culpepper, and Erin Stuckey for helpful discussions.
This work was supported by Bill and Melinda Gates through the Global Good Fund.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
- Systemic insecticide
- Mathematical modeling
- Malaria elimination
- Burden reduction
- Mass drug administration
- Seasonal malaria chemoprophylaxis